Nonalcoholic Fatty Liver Disease (NAFLD) in the Veterans Administration Population: Development and Validation of an Algorithm for NAFLD Using Automated Data
Overview
Pharmacology
Affiliations
Background: In practice, nonalcoholic fatty liver disease (NAFLD) is diagnosed based on elevated liver enzymes and confirmatory liver biopsy or abdominal imaging. Neither method is feasible in identifying individuals with NAFLD in a large-scale healthcare system.
Aim: To develop and validate an algorithm to identify patients with NAFLD using automated data.
Methods: Using the Veterans Administration Corporate Data Warehouse, we identified patients who had persistent ALT elevation (≥2 values ≥40 IU/mL ≥6 months apart) and did not have evidence of hepatitis B, hepatitis C or excessive alcohol use. We conducted a structured chart review of 450 patients classified as NAFLD and 150 patients who were classified as non-NAFLD by the database algorithm, and subsequently refined the database algorithm.
Results: The sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) for the initial database definition of NAFLD were 78.4% (95% CI: 70.0-86.8%), 74.5% (95% CI: 68.1-80.9%), 64.1% (95% CI: 56.4-71.7%) and 85.6% (95% CI: 79.4-91.8%), respectively. Reclassifying patients as having NAFLD if they had two elevated ALTs that were at least 6 months apart but within 2 years of each other, increased the specificity and PPV of the algorithm to 92.4% (95% CI: 88.8-96.0%) and 80.8% (95% CI: 72.5-89.0%), respectively. However, the sensitivity and NPV decreased to 55.0% (95% CI: 46.1-63.9%) and 78.0% (95% CI: 72.1-83.8%), respectively.
Conclusions: Predictive algorithms using automated data can be used to identify patients with NAFLD, determine prevalence of NAFLD at the system-wide level, and may help select a target population for future clinical studies in veterans with NAFLD.
Lo Re 3rd V, Newcomb C, Carbonari D, Mezochow A, Hennessy S, Rentsch C Pharmacoepidemiol Drug Saf. 2024; 33(12):e70069.
PMID: 39662972 PMC: 11634562. DOI: 10.1002/pds.70069.
Jose A, Rahman N, Opotowsky A, Glorioso T, Waldo S, Zeder K J Am Heart Assoc. 2024; 13(8):e033847.
PMID: 38567662 PMC: 11262483. DOI: 10.1161/JAHA.123.033847.
Exposure to Agent Orange and Hepatocellular Carcinoma Among US Military Personnel.
Benhammou J, Leng M, Shah S, Cholankeril G, Dong T, Patel A JAMA Netw Open. 2023; 6(12):e2346380.
PMID: 38048128 PMC: 10696483. DOI: 10.1001/jamanetworkopen.2023.46380.
Bangaru S, Sundaresh R, Lee A, Prause N, Hao F, Dong T Dig Dis Sci. 2023; 68(12):4474-4484.
PMID: 37864738 PMC: 10635943. DOI: 10.1007/s10620-023-08043-8.
Yamada-Shimizu M, Tamaki N, Kurosaki M, Uchihara N, Suzuki K, Tanaka Y Intern Med. 2023; 63(9):1185-1190.
PMID: 37779070 PMC: 11116030. DOI: 10.2169/internalmedicine.2248-23.